<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We investigated a dose-reduced conditioning regimen consisting of treosulfan and fludarabine followed by allogeneic stem cell transplantation (SCT) in 26 patients with <z:e sem="disease" ids="C0280449" disease_type="Neoplastic Process" abbrv="">secondary AML</z:e> or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Twenty patients were transplanted from matched or mismatched unrelated donors and six from HLA-identical sibling donors </plain></SENT>
<SENT sid="2" pm="."><plain>The median age of the patients was 60 years (range, 44-70) </plain></SENT>
<SENT sid="3" pm="."><plain>None of the patients was eligible for a standard myeloablative preparative regimen </plain></SENT>
<SENT sid="4" pm="."><plain>No graft-failure was observed, and leukocyte and platelet engraftment were observed after a median of 16 and 17 days, respectively </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0011009'>Acute</z:hpo> <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> (GvHD) grade II-IV was seen in 23% and severe grade III GvHD in 12% of the patients </plain></SENT>
<SENT sid="6" pm="."><plain>No patients experienced grade IV <z:hpo ids='HP_0011009'>acute</z:hpo> GvHD </plain></SENT>
<SENT sid="7" pm="."><plain><z:hpo ids='HP_0011010'>Chronic</z:hpo> GvHD was noted in 36% of the patients, which was <z:e sem="disease" ids="C0849867" disease_type="Disease or Syndrome" abbrv="">extensive disease</z:e> in 18% </plain></SENT>
<SENT sid="8" pm="."><plain>The 2-year cumulative incidence of relapse was 21% </plain></SENT>
<SENT sid="9" pm="."><plain>The relapse rate was higher in patients beyond CR1 or with intermediate two or high risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (P = 0.02) </plain></SENT>
<SENT sid="10" pm="."><plain>The treatment-related mortality at day 100 was 28% </plain></SENT>
<SENT sid="11" pm="."><plain>The 2-year estimated overall and disease-free survival was 36-34%, respectively </plain></SENT>
<SENT sid="12" pm="."><plain>No difference in survival was seen between unrelated and related SCT </plain></SENT>
</text></document>